Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024;31(4):564-572.
doi: 10.5603/cj.96228. Epub 2023 Sep 29.

Diagnostic value of soluble urokinase-type plasminogen activator receptor in patients with acute coronary syndrome: A systematic review and meta-analysis

Michal Pruc  1   2 , Iwona Jannasz  3 , Damian Swieczkowski  4 , Grzegorz Procyk  5 , Aleksandra Gasecka  5 , Zubaid Rafique  6 , Francesco Chirico  7 , Nicola Luigi Bragazzi  8 , Milosz J Jaguszewski  9 , Jaroslaw Wysocki  10 , Lukasz Szarpak  11   12   13
Affiliations
Meta-Analysis

Diagnostic value of soluble urokinase-type plasminogen activator receptor in patients with acute coronary syndrome: A systematic review and meta-analysis

Michal Pruc et al. Cardiol J. 2024.

Abstract

Background: In contemporary clinical practice, there is an increasing need for new clinically relevant biomarkers potentially optimizing management strategies in patients with suspected acute coronary syndrome (ACS). This study aimed to determine the diagnostic utility of soluble urokinase-type plasminogen activator receptor (suPAR) levels in individuals with suspected ACS.

Methods: A literature search was performed in Web of Science, PubMed, Scopus, and the Cochrane Central Register of Controlled Trials databases, for studies comparing suPAR levels among patients with and without ACS groups. The methodological quality of the included papers was assessed using the Newcastle-Ottawa Scale (NOS). A fixed-effects model was used if I² < 50%; otherwise, the random-effects model was performed.

Results: Five studies with 3417 participants were included in the meta-analysis. Pooled analysis showed that mean suPAR levels in the ACS group were statistically significantly higher than in the control group (3.56 ± 1.38 vs. 2.78 ± 0.54 ng/mL, respectively; mean difference: 1.04; 95% confidence interval: 0.64-1.44; I² = 99%; p < 0.001).

Conclusions: In the context of acute coronary syndrome, suPAR is a potential biomarker for the early identification of medical conditions in individuals who are being treated in emergency rooms.

Keywords: ACS; acute coronary syndrome; biomarker; meta-analysis; soluble urokinase plasminogen activator receptor; suPAR.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
The potential utility of soluble urokinase plasminogen activator receptor (suPAR) in acute coronary syndrome (ACS); CSF — cerebrospinal fluid; GPI — glycosyl-phosphatidylinositol; uPAR — urokinase plasminogen activator receptor
Figure 2
Figure 2
Flowchart detailing selection and screening of the studies included in this review
Figure 3
Figure 3
Forest plot of soluble urokinase plasminogen activator receptor (suPAR) values among patients with and without acute coronary syndrome (ACS). The center of each square represents the mean ratio for individual trials, and the corresponding horizontal line stands for the 95% confidence interval (CI). The diamonds represent pooled results; SD — standard difference
See this image and copyright information in PMC

References

    1. Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. 2022;327(7):662–675. doi: 10.1001/jama.2022.0358. - DOI - PubMed
    1. Sarkees ML, Bavry AA. Acute coronary syndrome (unstable angina and non-ST elevation MI) BMJ Clin Evid. 20092009 - PMC - PubMed
    1. Montalescot G, Dallongeville J, Van Belle E, et al. STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry) Eur Heart J. 2007;28(12):1409–1417. doi: 10.1093/eurheartj/ehm031. - DOI - PubMed
    1. Hamm CW, Bassand JP, Agewall S. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J. 2011;32:2999–3054. doi: 10.1093/eurheartj/ehr236. - DOI - PubMed
    1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J. 2018;39(2):119–177. doi: 10.1093/eurheartj/ehx393. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources